Fluorouracilum
Pancreatic Ductal Adenocarcinoma
Explore 280 assets in Pancreatic Ductal Adenocarcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619313CT.gov AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
NCT07621718CT.gov Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) | — | Recruiting | — | — | — |
NCT07283705CT.gov A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer | — | Recruiting | — | — | — |
NCT07214298CT.gov Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
NCT07030283CT.gov Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | — | Recruiting | — | — | — |
NCT07255404CT.gov A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer | — | Recruiting | — | — | — |
NCT07024615CT.gov A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | — | Recruiting | — | — | — |
NCT07284277CT.gov TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | — | Recruiting | — | — | — |
NCT07594964CT.gov To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | — | Recruiting | — | — | — |
NCT06913218CT.gov A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | — | Not Yet Recruiting | — | — | — |
Show 38 more trialsShow fewer
NCT07028424CT.gov PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment | — | Not Yet Recruiting | — | — | — |
NCT06648434CT.gov MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | — | Recruiting | — | — | — |
NCT06922591CT.gov Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06625320CT.gov Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | — | Active Not Recruiting | — | — | — |
NCT06598007CT.gov A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06586515CT.gov MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06428409CT.gov A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | — | Recruiting | — | — | — |
NCT06478862CT.gov Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | — | Terminated | — | — | — |
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
NCT06079346CT.gov A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT06219941CT.gov AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | — | Recruiting | — | — | — |
NCT06131840CT.gov A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05968326CT.gov A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | — | Recruiting | — | — | — |
NCT05482893CT.gov Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | — | Recruiting | — | — | — |
NCT05209074CT.gov Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05132504CT.gov Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05257993CT.gov Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT04990037CT.gov A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma | — | Completed | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT03806309CT.gov OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | — | Active Not Recruiting | — | — | — |
NCT04083599CT.gov GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03374852CT.gov CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | — | Withdrawn | — | — | — |
NCT01676259CT.gov A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | — | Unknown | — | — | — |
NCT03331640CT.gov A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy | — | Terminated | — | — | — |
NCT03221400CT.gov PEN-866 in Patients With Advanced Solid Malignancies | — | Unknown | — | — | — |
NCT02658214CT.gov Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02440958CT.gov Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | — | Completed | — | — | — |
NCT02405585CT.gov Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | — | Terminated | — | — | — |
NCT02125136CT.gov Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT01836432CT.gov Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | — | Terminated | — | — | — |
NCT01835041CT.gov CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01658943CT.gov Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | — | Completed | — | — | — |
NCT02575508CT.gov Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | Jonsson Comprehensive Cancer Center | P3 | B · 63 |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- DaraxonrasibRevolution Medicines, Inc.BB
- Rmc-6236Tango Therapeutics, Inc.BB
- S-1Genentech, Inc.BB
- MetforminBritish Columbia Cancer AgencyBB
Citation
Floatz Terminal. Fluorouracilum in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fluorouracilum-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →